{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T19:57:34Z","timestamp":1760385454519},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"11","funder":[{"name":"Lluita contra la SIDA Foundation (Barcelona, Spain)"},{"name":"\u2018Red Tem\u00e1tica de Investigaci\u00f3n en SIDA\u2019","award":["RIS, RD12\/0017"],"award-info":[{"award-number":["RIS, RD12\/0017"]}]},{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Antimicrob. Chemother."],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1093\/jac\/dkv205","type":"journal-article","created":{"date-parts":[[2015,10,22]],"date-time":"2015-10-22T20:27:23Z","timestamp":1445545643000},"page":"3087-3095","source":"Crossref","is-referenced-by-count":13,"title":["Virological failure to raltegravir in Spain: incidence, prevalence and clinical consequences"],"prefix":"10.1093","volume":"70","author":[{"given":"Jos\u00e9 Ram\u00f3n","family":"Santos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Luis","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar","family":"Masi\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F\u00e9lix","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Jes\u00fas","family":"P\u00e9rez-El\u00edas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Antonio","family":"Iribarren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lluis","family":"Force","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Antela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hernando","family":"Knobel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Salavert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Carlos","family":"L\u00f3pez Bernaldo De Quir\u00f3s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Pino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Paredes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bonaventura","family":"Clotet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2015,7,30]]},"reference":[{"key":"2015102114375164000_70.11.3087.1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31828ace69"},{"key":"2015102114375164000_70.11.3087.2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir510"},{"key":"2015102114375164000_70.11.3087.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708975"},{"key":"2015102114375164000_70.11.3087.4","doi-asserted-by":"publisher","DOI":"10.1086\/650002"},{"key":"2015102114375164000_70.11.3087.5","doi-asserted-by":"publisher","DOI":"10.1086\/630210"},{"key":"2015102114375164000_70.11.3087.6","unstructured":"European AIDS Clinical Society (EACS). Guidelines, Version 7.1, November 2014 . http:\/\/www.eacsociety.org\/files\/guidelines-7.1-english.pdf ."},{"key":"2015102114375164000_70.11.3087.7","author":"FDA"},{"key":"2015102114375164000_70.11.3087.8","volume-title":"Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents","year":"2015"},{"key":"2015102114375164000_70.11.3087.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60918-0"},{"key":"2015102114375164000_70.11.3087.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60917-9"},{"key":"2015102114375164000_70.11.3087.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61828-6"},{"key":"2015102114375164000_70.11.3087.12","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis750"},{"key":"2015102114375164000_70.11.3087.13","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu051"},{"key":"2015102114375164000_70.11.3087.14","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00470-08"},{"key":"2015102114375164000_70.11.3087.15","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02568-12"},{"key":"2015102114375164000_70.11.3087.16","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1750"},{"key":"2015102114375164000_70.11.3087.17","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181c42ea4"},{"key":"2015102114375164000_70.11.3087.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708978"},{"key":"2015102114375164000_70.11.3087.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60918-1"},{"key":"2015102114375164000_70.11.3087.20","first-page":"A62","article-title":"Prevalence and patterns of raltegravir resistance in treated patients in Europe [abstract]","volume":"15","author":"Geretti","year":"2010","journal-title":"Antivir Ther"},{"key":"2015102114375164000_70.11.3087.21","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku095"},{"key":"2015102114375164000_70.11.3087.22","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir636"},{"key":"2015102114375164000_70.11.3087.23","unstructured":"Vavro C , Huang J , Underwood M et al . Integrase genotypic and phenotypic predictors of antiviral response to dolutegravir (DTG) in subjects with resistance to integrase inhibitors (INIs). In: Abstracts of the International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies, Toronto, ON, 2013. Abstract 29, p. 37. University of California, San Diego School Medicine, La Jolla, CA, USA."},{"key":"2015102114375164000_70.11.3087.24","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit697"},{"key":"2015102114375164000_70.11.3087.25","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1748"},{"key":"2015102114375164000_70.11.3087.26","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1749"},{"key":"2015102114375164000_70.11.3087.27","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.7961"},{"key":"2015102114375164000_70.11.3087.28","doi-asserted-by":"publisher","DOI":"10.1086\/503914"},{"key":"2015102114375164000_70.11.3087.29","unstructured":"Nichols G , Lazzarin A , Maggiolo F et al . Phase 3 assessment of dolutegravir (DTG) 50 mg twice daily (BID) in HIV-1-infected subjects with raltegravir (RAL) and\/or elvitegravir (EVG) resistance in VIKING-3: week 24 results of all 183 subjects enrolled. In: Abstracts of the Seventh IAS Conference on HIV Pathogenesis, Treatment and Prevention, Kuala Lumpur, 2013. Abstract TULBPE19. International AIDS Society, Geneva, Switzerland."},{"key":"2015102114375164000_70.11.3087.30","unstructured":"Team RDC. R: A Language and Environment for Statistical Computing . 2010. http:\/\/www.r-project.org ."},{"key":"2015102114375164000_70.11.3087.31","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181da1287"},{"key":"2015102114375164000_70.11.3087.32","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(11)70196-7"},{"key":"2015102114375164000_70.11.3087.33","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181c990bf"},{"key":"2015102114375164000_70.11.3087.34","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32830285fb"},{"key":"2015102114375164000_70.11.3087.35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0906768"},{"key":"2015102114375164000_70.11.3087.36","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32832cbcc2"},{"key":"2015102114375164000_70.11.3087.37","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000162334.12815.5b"},{"key":"2015102114375164000_70.11.3087.38","doi-asserted-by":"publisher","DOI":"10.1186\/1742-6405-4-11"},{"key":"2015102114375164000_70.11.3087.39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0084276"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/70\/11\/3087\/6991803\/dkv205.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T00:40:49Z","timestamp":1589589649000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article-lookup\/doi\/10.1093\/jac\/dkv205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,30]]},"references-count":39,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2015,10,12]]},"published-print":{"date-parts":[[2015,11]]}},"alternative-id":["10.1093\/jac\/dkv205"],"URL":"https:\/\/doi.org\/10.1093\/jac\/dkv205","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,30]]}}}